Markets:

Overview

News

Currencies

International

Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

23.93 -0.34 (-1.40%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Exelixis Stock Sees Rising Relative Strength Rating ↗

August 14, 2023

On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before.

Via Investor's Business Daily

5 Analysts Have This to Say About Catalyst Pharmaceuticals ↗

August 11, 2023

Via Benzinga

7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now ↗

August 03, 2023

Although ultra-cheap ideas tend to carry significant risks, these strong buy value stocks offer the endorsement of analysts.

Via InvestorPlace

Where Catalyst Pharmaceuticals Stands With Analysts ↗

July 21, 2023

Via Benzinga

7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing ↗

July 02, 2023

Although people might not readily recognize these little-known stocks, they offer surprisingly robust upside potential.

Via InvestorPlace

ETF Returns: Mid-Cap Winners And Losers ↗

June 28, 2023

We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on...

Via Benzinga

The Latest Analyst Ratings for Catalyst Pharmaceuticals ↗

June 21, 2023

Via Benzinga

Catalyst Pharmaceuticals: Q1 Earnings Insights ↗

May 10, 2023

Via Benzinga

Truist Securities Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know ↗

June 21, 2023

Via Benzinga

The 7 Best Stocks Under $15 to Buy in June 2023 ↗

June 01, 2023

While you generally get what you pay for, these best stocks under $15 for June provide compelling opportunities at discount.

Via InvestorPlace

Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy? ↗

May 22, 2023

When evaluating investments, it helps to keep quarterly performance in context.

Via The Motley Fool

Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

May 15, 2023

Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.

Via Investor's Business Daily

Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review ↗

May 12, 2023

The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones.

Via Investor's Business Daily

1 Growth Stock to Buy Before the Next Bull Market ↗

April 04, 2023

The stock is on a roll, and the company just made a major new purchase.

Via The Motley Fool

Analyst Expectations for Catalyst Pharmaceuticals's Future ↗

March 20, 2023

Via Benzinga

Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

May 11, 2023

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales.

Via Benzinga

IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth ↗

May 11, 2023

Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits.

Via Investor's Business Daily

4 Analysts Have This to Say About Catalyst Pharmaceuticals ↗

March 20, 2023

Via Benzinga

Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

March 16, 2023

Via Benzinga

Earnings Outlook For Catalyst Pharmaceuticals ↗

March 14, 2023

Via Benzinga

7 A-Rated Stocks to Buy for April 2023 ↗

April 07, 2023

Now that the first quarter's in the bank, here are seven A-rated stocks to buy for April to keep your portfolio in top-notch shape.

Via InvestorPlace

2 Top Growth Stocks That Can Withstand an Economic Downturn ↗

April 05, 2023

These two drugmakers should march higher in 2023 and beyond.

Via The Motley Fool

Why Catalyst Pharmaceuticals Shares Are Moving ↗

March 16, 2023

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading higher by 9.66% to $15.72 Thursday morning after the company reported better-than-expected fourth-quarter results.

Via Benzinga

Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates ↗

March 15, 2023

The guidance includes Catalyst's newest, and second, product.

Via Investor's Business Daily

7 Core Stocks to Build a Solid Portfolio Around ↗

March 13, 2023

You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation.

Via InvestorPlace

Earnings Scheduled For March 15, 2023 ↗

March 15, 2023

Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.

Via Benzinga

2 Growth Stocks to Invest $1,000 in Right Now ↗

March 03, 2023

Both of these biopharmas have major catalysts that are in play or drawing near.

Via The Motley Fool

2 Breakout Growth Stocks to Buy for the Long Haul ↗

March 03, 2023

These two stocks are entirely different, but they both make shareholders richer.

Via The Motley Fool

7 Smart Stock Picks for Cautious Investors ↗

February 28, 2023

As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors.

Via InvestorPlace

Catalyst Pharma Reveals Interim Q4 Earnings, Says Well Positioned For 2023 ↗

February 07, 2023

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

Headline News about Catalyst Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today